PredictIt

PredictIt's most useful distinction is in the CFTC paperwork: its academic event market operates within a conditional staff no-action framework. The original October 2014 letter explained that staff would not recommend enforcement for operating without the specified exchange registrations, subject to its conditions. That is a narrower statement than saying the CFTC has granted a conventional exchange licence or endorsed the safety of trading.

The July 2025 amendment removed the old ceiling of 5,000 traders in an individual contract and linked each participant's investment limit to the federal individual campaign-contribution limit, stated in that letter as $3,500. These address different constraints: more people can enter a contract, while each person's investment remains capped. The amendment allowed transfer of the market from Victoria University of Wellington to the US nonprofit Prediction Market Research Consortium. It does not, by itself, prove when that transfer was completed.

The same amendment describes political questions extending beyond elections to government appointments, legislation and certain court decisions. War, terrorism and assassination are excluded. Its footnote preserves the original letter's separate treatment of economic-indicator contracts. The scope is therefore more precise than a blanket claim that PredictIt covers any future event.

The original framework described contracts paying $1 for the correct outcome and nothing for an incorrect outcome. That structure is why a quoted price must be read alongside the exact resolution condition: a position on the wrong outcome can finish with no payout. The letter also expressly declined to decide compliance with state law and reserved staff's ability to alter or withdraw relief.

Bookie Hunt's assessment centres on these written limits and conditions. PredictIt's FAQ did not yield readable fee or funding terms during this research, so this draft makes no claim about current withdrawal charges, deposit minimums or app availability. The regulatory letters cannot fill those product-information gaps.